Among stable patients undergoing cardiac catheterization, the majority (59%) have little or no angiographic abnormality, as shown in the visual1 in spite of the fact that the majority have symptoms of a coronary disorder.2 Patients with ischemia and no obstructive artery disease (INOCA) may have coronary microvascular dysfunction (CMD). As a group, these patients are underdiagnosed.
The index of microcirculatory resistance (IMR) and coronary flow reserve (CFR) are used to assess the microvasculature to help provide a diagnosis of CMD.
When an interventional cardiologist (IC) injects saline flush at ambient temperature into the artery, the PressureWire™ X Guidewire detects temperature changes as the saline passes the proximal and distal sensors.
Coronary flow is estimated based on the time it takes the saline to pass between proximal and distal sensors. This time (in seconds) is known as the Mean Transit Time (Tmn).
Green indicates normal values, red indicates abnormal values
Cutoff values are specific for INOCA patients
As the CorMicA study reveals, patients may benefit when coronary microvascular dysfunction is accurately diagnosed and properly treated.8,13
In addition, a comprehensive physiology assessment was demonstrated to be highly cost-effective at £4,500 per QALY. This is well below the accepted cost-effectiveness threshold of £20,000 per QALY for NICE (UK).14-16
Proper assessment, diagnosis, and treatment of CMD can improve outcomes in CMD patients at high risk for MACE and reduce healthcare burden.3,9,17
ESC and ACC/AHA guidelines recommend measuring IMR and CFR using a guidewire-based approach for symptomatic patients who exhibit no significant evidence of epicardial stenosis.
The ESC guidelines18 2019 were updated accordingly to include an increased focus on microvascular dysfunction.
| RECOMMENDATIONS | CLASSa | Levelb |
| Guidewire-based CFR and/or microcirculatory resistance measurements should be considered in patients with persistent symptoms, but coronary arteries that are either angiographically normal or have moderate stenosis with preserved iwFR/FFR | IIa | B |
The AHA/ACC Clinical Practice Guideline on chest pain includes Class IIa recommendation for guidewire-based assessment for INOCA patients.19
| RECOMMENDATIONS FOR PATIENTS WITH INOCA | CLASSa | Levelb |
| For patients with persistent stable chest pain and non-obstructive CAD and at least mild myocardial ischemia on imaging, it is reasonable to consider invasive coronary function testing to improve the diagnosis of coronary microvascular dysfunction and to enhance risk stratification. | IIa | B-NR |
CFR = coronary flow reserve; CMR = cardiac magnetic resonance; ECG = electrocardiogram;
FFR = fractional flow reserve; iwFR = instantaneous wave-free ratio; LAD = left anterior descending; PET = positron emission tomography.
a Class of recommendation.
b Level of evidence.
Level-NR: Level (Quality) of Evidence Level B-NR (non-randomized): moderate-quality evidence from 1 or more well designed, well executed non-randomized studies, observational studies or registry studies. RCTs. Meta-analyses of such studies.
The PressureWire™ X Guidewire with CoroFlow‡ Cardiovascular System has the capability to wirelessly measure comprehensive physiology indices to assess for epicardial disease (FFR, RFR) and microvascular dysfunction (IMR, CFR).4,7
MAT-2211668 v1.0
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.
Do you want to continue?